The Efficacy Arms Race Has a New Ceiling — And Novo Nordisk Just Set It
Wegovy HD's FDA approval at 7.2 mg delivers 20.7% mean weight loss — but the real story isn't the...
Moe Alsumidaie
AbbVie’s Post-Humira Safety Net Has a Hole in It — and J&J Just Found It
BNP Paribas flagged J&J's oral psoriasis candidate as a credible Skyrizi rival, and Wall Street mostly shrugged. They shouldn't...
Pfizer’s R&D Reset Isn’t a Strategy — It’s a Symptom of Something Bigger
Chris Boshoff's public pivot toward oncology and obesity signals more than a pipeline refresh at Pfizer. Three converging moves...
The FDA’s Public Accusation Against uniQure Is a Precedent-Setting Threat to Scientific Dialogue
The FDA just accused a sponsor of pushing distorted data to conceal a failed gene therapy — publicly, on...
Navigating the 2026 Biotech Macro Environment and Strategic Execution
At the 2026 SCOPE Summit, Scott Megaffin, CEO of Adiso Therapeutics, detailed a transition from the economic ebb of...
Capital Markets and European Biotech: Navigating the Multi-Billion Dollar Innovation Cycle
The global life sciences sector is currently navigating a significant transition in capital market dynamics, shifting from a period...
Abivax Strategic Turnaround: From Near Bankruptcy to Record-Breaking Biotech Funding
At a featured session during the 2025 BIO-Europe conference, leaders from Abivax and Sofinnova Partners detailed the dramatic transformation...
As US Research Recedes, What is Future of Biotech in Europe?
At the 2025 BIO Europe Summit, David Lowe, CEO of Ipsen, and Jeremy Levin, Chairman Emeritus of BIO, explored...
Novartis Streamlines Corporate Strategy to Accelerate High-Value Deal Execution
At 2025 BIO-Europe, it was clear that the pharmaceutical landscape had witnessed a significant shift in deal-making velocity, with...
Why 2026 is the Best of Times for Big Pharma and the Worst of Times for Biotech
In Washington, the ink was barely dry on a landmark domestic manufacturing deal for Pfizer. In San Diego, a...